Pharmaceutical Executive
July 01, 2004
Features
Critics often claim that international marketing programs ignore fundamental differences that exist across countries and cultures.
July 01, 2004
Features
In 2003, Big Pharma produced only a dozen new drugs. At the same time, it came under new pressure to create value from those thin pipelines. In that "hot squeeze" of a climate, pharma companies needed price premiums for every product in every market. They were more successful in some countries than in others. Other pricing trends also took their toll.
July 01, 2004
Features
Big pharma companies aggressively gather sensitive intelligence about their competitors, but few, strangely, make a systematic effort to protect their own.